MARCHF3

Summary

MARCHF3 (membrane associated ring-CH-type finger 3, HGNC:28728) is a protein-coding gene on chromosome 5q23.2, encoding E3 ubiquitin-protein ligase MARCHF3 (Q86UD3). E3 ubiquitin-protein ligase which may be involved in endosomal trafficking.

This gene encodes a member of the membrane-associated RING-CH (MARCH) family. The encoded protein is an E3 ubiquitin-protein ligase that may be involved in regulation of the endosomal transport pathway.

Source: NCBI Gene 115123 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 37 total
• MANE Select transcript: NM_178450

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28728
Approved symbol	MARCHF3
Name	membrane associated ring-CH-type finger 3
Location	5q23.2
Locus type	gene with protein product
Status	Approved
Aliases	MGC48332, MARCH-III, RNF173
Ensembl gene	ENSG00000173926
Ensembl biotype	protein_coding
OMIM	613333
Entrez	115123

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 9 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000308660, ENST00000502289, ENST00000504239, ENST00000506088, ENST00000515241, ENST00000892692, ENST00000892693, ENST00000892694, ENST00000928509, ENST00000928510, ENST00000928511, ENST00000968913

RefSeq mRNA: 1 — MANE Select: NM_178450 NM_178450

CCDS: CCDS4141

Canonical transcript exons

ENST00000308660 — 5 exons

Exon	Start	End
ENSE00001178483	126878185	126878394
ENSE00001178489	126914930	126915134
ENSE00001242174	127030350	127030558
ENSE00001242185	126867714	126870791
ENSE00003676575	126917984	126918227

Expression profiles

Bgee: expression breadth ubiquitous, 227 present calls, max score 91.95.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.5785 / max 337.6123, expressed in 1687 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
63209	15.3246	1632
63210	0.9670	567
63211	0.1993	56
63208	0.0489	10
63206	0.0339	14
63212	0.0049	2

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	91.95	silver quality
sperm	CL:0000019	91.10	gold quality
left testis	UBERON:0004533	90.05	gold quality
right testis	UBERON:0004534	89.71	gold quality
skin of leg	UBERON:0001511	89.13	gold quality
heart left ventricle	UBERON:0002084	88.61	gold quality
testis	UBERON:0000473	88.56	gold quality
cardiac ventricle	UBERON:0002082	88.32	gold quality
skin of abdomen	UBERON:0001416	88.31	gold quality
male germ cell	CL:0000015	88.00	gold quality
apex of heart	UBERON:0002098	87.58	gold quality
adrenal tissue	UBERON:0018303	87.22	gold quality
right atrium auricular region	UBERON:0006631	87.21	gold quality
zone of skin	UBERON:0000014	87.08	gold quality
mucosa of transverse colon	UBERON:0004991	85.95	gold quality
omental fat pad	UBERON:0010414	85.95	gold quality
peritoneum	UBERON:0002358	85.90	gold quality
heart	UBERON:0000948	85.85	gold quality
rectum	UBERON:0001052	85.83	gold quality
adipose tissue of abdominal region	UBERON:0007808	85.34	gold quality
gall bladder	UBERON:0002110	85.29	gold quality
heart right ventricle	UBERON:0002080	85.14	gold quality
cardiac atrium	UBERON:0002081	85.10	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.83	gold quality
mucosa of sigmoid colon	UBERON:0004993	84.82	gold quality
cortical plate	UBERON:0005343	84.79	gold quality
colonic mucosa	UBERON:0000317	84.34	gold quality
lower esophagus mucosa	UBERON:0035834	84.05	gold quality
epithelial cell of pancreas	CL:0000083	83.46	gold quality
medial globus pallidus	UBERON:0002477	83.26	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-10042	yes	24.58
E-GEOD-135922	yes	9.48
E-HCAD-25	yes	4.77
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

127 targeting MARCHF3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-1271-5P	99.91	71.99	1972

Literature-anchored findings (GeneRIF, showing 3)

• LPS activation of TLR4 significantly increased MARCH3 expression and that siRNA against MARCH3 prevented the decrease in FcgammaRIIb following LPS treatment. (PMID:26694610)
• Report shows that silencing MARCH3 protects the endothelial barrier and upregulates OCLN in MARCH3-depleted cells. MARCH3 silencing results in the strengthening of cell-cell contacts and inactivates FoxO1. (PMID:27616439)
• RNF173 suppresses RAF/MEK/ERK signaling to regulate invasion and metastasis via GRB2 ubiquitination in Hepatocellular Carcinoma. (PMID:37626338)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	zgc:158785	ENSDARG00000062959
mus_musculus	Marchf3	ENSMUSG00000032656
rattus_norvegicus	Marchf3	ENSRNOG00000023013
caenorhabditis_elegans	marc-3	WBGENE00007643

Paralogs (6): MARCHF2 (ENSG00000099785), MARCHF9 (ENSG00000139266), MARCHF4 (ENSG00000144583), MARCHF1 (ENSG00000145416), MARCHF8 (ENSG00000165406), MARCHF11 (ENSG00000183654)

Protein

Protein identifiers

E3 ubiquitin-protein ligase MARCHF3 — Q86UD3 (reviewed: Q86UD3)

Alternative names: Membrane-associated RING finger protein 3, Membrane-associated RING-CH protein III, RING finger protein 173, RING-type E3 ubiquitin transferase MARCHF3

All UniProt accessions (1): Q86UD3

UniProt curated annotations — full annotation on UniProt →

Function. E3 ubiquitin-protein ligase which may be involved in endosomal trafficking. E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfer the ubiquitin to targeted substrates.

Subunit / interactions. Interacts with MARCHF2 and STX6.

Subcellular location. Cytoplasmic vesicle membrane. Early endosome membrane.

Domain organisation. The RING-CH-type zinc finger domain is required for E3 ligase activity.

Pathway. Protein modification; protein ubiquitination.

Isoforms (2)

UniProt ID	Names	Canonical?
Q86UD3-1	1	yes
Q86UD3-2	2

RefSeq proteins (1): NP_848545* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001841	Znf_RING	Domain
IPR011016	Znf_RING-CH	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily

Pfam: PF12906

UniProt features (17 total): binding site 8, transmembrane region 2, modified residue 2, splice variant 2, chain 1, sequence variant 1, zinc finger region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86UD3-F1	71.56	0.34

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 113; 116; 71; 74; 87; 89; 97; 100

Post-translational modifications (2): 237, 243

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 186 (showing top): GSE45365_NK_CELL_VS_BCELL_DN, TAATAAT_MIR126, PEREZ_TP63_TARGETS, GOBP_VESICLE_MEDIATED_TRANSPORT, TAL1ALPHAE47_01, DOANE_BREAST_CANCER_CLASSES_DN, TGTGTGA_MIR377, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, ONDER_CDH1_TARGETS_2_UP, BOYAULT_LIVER_CANCER_SUBCLASS_G1_UP, AACTTT_UNKNOWN, PEREZ_TP53_AND_TP63_TARGETS, LIU_CMYB_TARGETS_UP, GOBP_IMPORT_INTO_CELL, LIU_VMYB_TARGETS_UP

GO Biological Process (2): endocytosis (GO:0006897), protein ubiquitination (GO:0016567)

GO Molecular Function (6): ubiquitin-protein transferase activity (GO:0004842), zinc ion binding (GO:0008270), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (6): lysosome (GO:0005764), endosome (GO:0005768), early endosome membrane (GO:0031901), membrane (GO:0016020), cytoplasmic vesicle membrane (GO:0030659), cytoplasmic vesicle (GO:0031410)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasmic vesicle	2
vesicle budding from membrane	1
membrane invagination	1
vesicle-mediated transport	1
import into cell	1
protein modification by small protein conjugation	1
ubiquitin-like protein transferase activity	1
transition metal ion binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
catalytic activity	1
cation binding	1
lytic vacuole	1
endomembrane system	1
early endosome	1
endosome membrane	1
cellular anatomical structure	1
vesicle membrane	1
cytoplasm	1
intracellular vesicle	1

Protein interactions and networks

STRING

644 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MARCHF3	STX6	O43752	907
MARCHF3	TGOLN2	O43493	777
MARCHF3	MARCHF10	Q8NA82	627
MARCHF3	SPMIP10	Q6ZNM6	573
MARCHF3	C5orf63	A6NC05	570
MARCHF3	TFRC	P02786	563
MARCHF3	MARCHF7	Q9H992	489
MARCHF3	MINAR2	P59773	432
MARCHF3	HSPB3	Q12988	428
MARCHF3	GRAMD2B	Q96HH9	404
MARCHF3	MARCHF5	Q9NX47	398
MARCHF3	TMEM215	Q68D42	388
MARCHF3	VAMP3	Q15836	367
MARCHF3	LRP2BP	Q9P2M1	357
MARCHF3	ISOC1	Q96CN7	350

IntAct

136 interactions, top by confidence:

A	B	Type	Score
DLG1	MARCHF3	psi-mi:“MI:0915”(physical association)	0.610
MARCHF3	DLG1	psi-mi:“MI:0407”(direct interaction)	0.610
MARCHF3	APOL2	psi-mi:“MI:0915”(physical association)	0.560
MARCHF3	FATE1	psi-mi:“MI:0915”(physical association)	0.560
UBE2K	MARCHF3	psi-mi:“MI:0915”(physical association)	0.560
MARCHF3	DLG2	psi-mi:“MI:0407”(direct interaction)	0.440
MARCHF3	DLG4	psi-mi:“MI:0407”(direct interaction)	0.440
MARCHF3	MAGI3	psi-mi:“MI:0407”(direct interaction)	0.440
MARCHF3	DLG3	psi-mi:“MI:0407”(direct interaction)	0.440
MARCHF3	SNTA1	psi-mi:“MI:0407”(direct interaction)	0.440
MARCHF3	SNX27	psi-mi:“MI:0407”(direct interaction)	0.440
MARCHF3	MAGI2	psi-mi:“MI:0407”(direct interaction)	0.440
MARCHF3	LNX2	psi-mi:“MI:0407”(direct interaction)	0.440
MARCHF3	SNTB1	psi-mi:“MI:0407”(direct interaction)	0.440
MARCHF3	PDZD7	psi-mi:“MI:0407”(direct interaction)	0.440
MARCHF3	PTPN3	psi-mi:“MI:0407”(direct interaction)	0.440
MARCHF3	SYNJ2BP	psi-mi:“MI:0407”(direct interaction)	0.440
MARCHF3	MAST2	psi-mi:“MI:0407”(direct interaction)	0.440
MARCHF3	MAGI1	psi-mi:“MI:0407”(direct interaction)	0.440
MARCHF3	GORASP2	psi-mi:“MI:0407”(direct interaction)	0.440
MARCHF3	SCRIB	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (55): MARCH3 (Two-hybrid), MARCH3 (Two-hybrid), BAG2 (Affinity Capture-MS), ILF3 (Affinity Capture-MS), TFRC (Affinity Capture-MS), TMEM201 (Affinity Capture-MS), RNFT1 (Affinity Capture-MS), NDUFS2 (Affinity Capture-MS), TNFRSF10B (Affinity Capture-MS), ITCH (Affinity Capture-MS), NOTCH2 (Affinity Capture-MS), NCSTN (Affinity Capture-MS), SLC3A2 (Affinity Capture-MS), ENDOD1 (Affinity Capture-MS), ATF6B (Affinity Capture-MS)

ESM2 similar proteins: A0A571BF63, A0JMQ9, A0JN69, A1L1R5, E7EZI4, O41933, P0C7U3, P33279, P40145, P97490, Q0IH10, Q0VD59, Q11122, Q1L8G6, Q1LVZ2, Q28EX7, Q28GL3, Q28IK8, Q32L65, Q3UF64, Q4R8E0, Q5I0I2, Q5M7Z0, Q5PQ35, Q5RAG4, Q5T0T0, Q5XH39, Q5XIE5, Q68FA7, Q6NRX0, Q6NTV1, Q6NZ21, Q6NZQ8, Q6ZPS6, Q6ZUJ8, Q803Q4, Q86UD3, Q8BGN6, Q8BPQ7, Q8BRX9

Diamond homologs: A0JN69, A6NNE9, A6P320, F4JKK0, O60103, O60337, P40318, P90489, P90495, Q0IH10, Q0P496, Q0VD59, Q1LVZ2, Q28EX7, Q32L65, Q3TZ87, Q5I0I2, Q5PQ35, Q5R9W1, Q5T0T0, Q5XIE5, Q5XIV2, Q68FA7, Q6NZQ8, Q6ZQ89, Q80TE3, Q86UD3, Q86YJ5, Q8BRX9, Q8CBH7, Q8TCQ1, Q99M02, Q9DBD2, Q9P0N8, Q9P2E8, Q0X0A5, Q28IK8, Q3KNM2, Q3ZC24, Q5R9W2

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	MARCHF3	ubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 87 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Assembly and cell surface presentation of NMDA receptors	8	36.2×	4e-09
Neurexins and neuroligins	10	35.2×	3e-11
Protein-protein interactions at synapses	6	28.5×	4e-06
Antigen processing: Ubiquitination & Proteasome degradation	9	6.0×	3e-04

GO biological processes:

GO term	Partners	Fold	FDR
establishment or maintenance of epithelial cell apical/basal polarity	9	63.0×	5e-12
protein localization to synapse	6	55.4×	2e-07
receptor clustering	6	45.1×	4e-07
regulation of postsynaptic membrane neurotransmitter receptor levels	6	35.8×	2e-06
protein-containing complex assembly	9	12.3×	3e-06
protein K48-linked ubiquitination	6	12.2×	5e-04
cell-cell adhesion	8	9.8×	1e-04
chemical synaptic transmission	7	6.5×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

37 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	31
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1651 predictions. Top by Δscore:

Variant	Effect	Δscore
5:126917983:CCT:C	donor_gain	1.0000
5:126918006:C:CT	donor_gain	1.0000
5:126918006:CTA:C	donor_gain	1.0000
5:126918007:T:TT	donor_gain	1.0000
5:126918054:A:AC	donor_gain	1.0000
5:126918055:C:CC	donor_gain	1.0000
5:126878183:A:AC	donor_gain	0.9900
5:126878184:C:CC	donor_gain	0.9900
5:126878390:AGCCA:A	acceptor_gain	0.9900
5:126878399:CAGG:C	acceptor_gain	0.9900
5:126913301:T:TA	donor_gain	0.9900
5:126914924:A:AC	donor_gain	0.9900
5:126914925:C:CC	donor_gain	0.9900
5:126917978:TACTA:T	donor_loss	0.9900
5:126917979:ACTAC:A	donor_loss	0.9900
5:126917981:TAC:T	donor_loss	0.9900
5:126917982:ACCTC:A	donor_loss	0.9900
5:126917983:C:CA	donor_loss	0.9900
5:126918008:A:AC	donor_gain	0.9900
5:126918009:C:CC	donor_gain	0.9900
5:126918029:T:TA	donor_gain	0.9900
5:126918045:G:A	donor_gain	0.9900
5:126918224:CCAT:C	acceptor_gain	0.9900
5:126918225:CAT:C	acceptor_gain	0.9900
5:126918225:CATC:C	acceptor_gain	0.9900
5:126918228:C:CC	acceptor_gain	0.9900
5:126870791:CCT:C	acceptor_loss	0.9800
5:126870792:CTG:C	acceptor_loss	0.9800
5:126878184:CTA:C	donor_gain	0.9800
5:126878391:GCCA:G	acceptor_gain	0.9800

AlphaMissense

1632 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:126870753:C:A	W214C	1.000
5:126870753:C:G	W214C	1.000
5:126870755:A:G	W214R	1.000
5:126870755:A:T	W214R	1.000
5:126878193:A:G	W199R	1.000
5:126878193:A:T	W199R	1.000
5:126878225:A:G	L188P	1.000
5:126878225:A:T	L188H	1.000
5:126878234:A:G	L185P	1.000
5:126878292:A:G	C166R	1.000
5:126878294:A:G	L165P	1.000
5:126878300:C:T	G163D	1.000
5:126878312:G:T	A159D	1.000
5:126878318:G:C	P157R	1.000
5:126878324:A:T	I155K	1.000
5:126878345:T:G	D148A	1.000
5:126914964:A:G	F120S	1.000
5:126914975:G:C	C116W	1.000
5:126914976:C:A	C116F	1.000
5:126914976:C:G	C116S	1.000
5:126914976:C:T	C116Y	1.000
5:126914977:A:G	C116R	1.000
5:126914977:A:T	C116S	1.000
5:126914984:A:C	C113W	1.000
5:126914985:C:A	C113F	1.000
5:126914985:C:G	C113S	1.000
5:126914985:C:T	C113Y	1.000
5:126914986:A:G	C113R	1.000
5:126914986:A:T	C113S	1.000
5:126915009:A:G	L105P	1.000

dbSNP variants (sampled 300 via entrez): RS1000016749 (5:126887998 A>C,G), RS1000040125 (5:126894362 G>A,C), RS1000067227 (5:126937359 C>A,T), RS1000070993 (5:126980880 G>T), RS1000109485 (5:127000113 A>G), RS1000122980 (5:126917907 T>G), RS1000128944 (5:126926946 T>A), RS1000172122 (5:126928060 A>G), RS1000209011 (5:126872057 G>A), RS1000215133 (5:126869798 C>T), RS1000246442 (5:127013460 T>C), RS1000296600 (5:126880970 T>C), RS1000302519 (5:126881599 T>G), RS1000327086 (5:126899955 A>G), RS1000337602 (5:126874723 T>A,C,G)

Disease associations

OMIM: gene MIM:613333 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST008534_1	Hearing loss in Charcot-Marie-Tooth disease 1A	2.000000e-07
GCST009240_392	Serum metabolite levels (CMS)	4.000000e-10
GCST009242_200	Serum metabolite levels	2.000000e-06
GCST009462_62	Optic disc size	1.000000e-08
GCST009531_6	Body fat percentage	9.000000e-08
GCST010436_4	Type 2 diabetes	1.000000e-07
GCST90002387_307	Immature fraction of reticulocytes	2.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007800	body fat percentage

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	increases expression	4
Valproic Acid	increases expression	3
entinostat	increases expression, affects cotreatment	2
Benzo(a)pyrene	increases methylation, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Silicon Dioxide	increases expression	2
aristolochic acid I	increases expression	1
GSK-J4	increases expression	1
aminomethylphosphonic acid (AMPA)	decreases expression	1
propionaldehyde	increases expression	1
bisphenol A	decreases expression	1
sodium arsenite	affects methylation	1
cobaltous chloride	decreases expression	1
butyraldehyde	increases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
hydroquinone	increases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	1
abrine	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
dorsomorphin	increases expression, decreases expression, affects cotreatment	1
Dasatinib	decreases expression	1
Zoledronic Acid	increases expression	1
Arsenic Trioxide	decreases expression	1
Acetaminophen	increases expression	1
Calcitriol	increases expression	1
Catechin	affects cotreatment, increases expression	1
Cytarabine	decreases expression	1
Lipopolysaccharides	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.